Newsroom

Industry News

30 Oct

GeoVax Presents HIV Vaccine Clinical Trial Data

Results of HIV Immunotherapy Vaccine Trial Presented at HIVR4P Conference GeoVax Labs, Inc. (GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., gave an oral presentation entitled Elicitation of Immune Responses by a...

Read more

30 Oct

GeoVax CEO Interviewed on the Fox Business Network

Watch Robert McNally Discuss GeoVax’s Ebola Vaccine Program Robert T. McNally, PhD, President & CEO of GeoVax Labs, Inc. (GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, was recently interviewed on the Fox Business Network’s The Willis Report and on MONEY with Melissa...

Read more

30 Oct

Celator(R) Pharmaceuticals to Present on Liposome Delivery Systems at 2014 American Association of Pharmaceutical Scientists Annual Meeting

Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Dr. Lawrence Mayer, President, Founder and Chief Scientific Officer of Celator, will present at the 2014 American Association of Pharmaceutical Scientists (AAPS)...

Read more

28 Oct

Cesca Therapeutics Shareholders Reporting Group File 13D

A Schedule 13D has been filed with the U.S. Securities and Exchange Commission on behalf of a group of shareholders in Cesca Therapeutics, a company formed by the merger earlier this year of leading cell-therapy device-maker ThermoGenesis Corp. and regenerative medicine clinical therapy company TotipotentRX, engaged in the research,...

Read more

27 Oct

Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an “Acceptable” Classification

Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration (“FDA”) has provided the Company with written notification that its Toronto, Canada manufacturing...

Read more

27 Oct

Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to Market

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, has signed a $500,000 Securities Purchase Agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”),...

Read more

27 Oct

Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an “Acceptable” Classification

Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration (“FDA”) has provided the Company with written notification that its Toronto, Canada manufacturing...

Read more

Page 1 of 2512345...1020...Last »

Latest Tweets